查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1128746

膀胱功能不全的全球市場 - 產業趨勢和2029年為止的預測

Global Underactive Bladder Market - Industry Trends and Forecast to 2029
出版日期: | 出版商: Data Bridge Market Research | 英文 411 Pages | 商品交期: 請詢問到貨日

價格

全球膀胱功能不全的市場規模在2022年～2029年的預測期間預計將以5.1％的年複合成長率擴大。

本報告提供全球膀胱功能不全市場相關調查，市場概要，以及各類型，各給藥途徑，各終端用戶，各流通管道，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 簡介

第2章 市場區隔

第3章 摘要整理

第4章 重要考察

第5章 全球膀胱功能不全市場:法規

第6章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題

第7章 全球膀胱功能不全市場，各類型

  • 概要
  • 藥物療法
  • 外科的方法
  • 尿道輔助器具
  • 幹細胞治療和基因治療

第8章 全球膀胱功能不全市場，各給藥途徑

  • 概要
  • 非口服
  • 口服
  • 其他

第9章 全球膀胱功能不全市場，各終端用戶

  • 概要
  • 醫院
  • 診所
  • 學術研究機關
  • 其他

第10章 全球膀胱功能不全市場，各流通管道

  • 概要
  • 院內藥局
  • 零售藥局
  • 其他

第11章 全球膀胱功能不全市場，各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第12章 全球膀胱功能不全市場:企業形勢

  • 企業佔有率分析:世界
  • 企業佔有率分析:北美
  • 企業佔有率分析:歐洲
  • 企業佔有率分析:亞太地區

第13章 SWOT分析

第14章 企業簡介

  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • PFIZER INC.
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • NOVARTIS AG
  • DR. REDDY'S LABORATORIES LTD.
  • ASTELLAS PHARMA INC.
  • ORION CORPORATION.
  • ALKEM LABS.
  • ALMIRALL, S.A
  • AUROBINDO PHARMA.
  • CIPLA INC.
  • GLENWOOD
  • MACLEODS PHARMACEUTICALS LTD.
  • ONO PHARMACEUTICAL CO., LTD.

第15章 詢問調查

第16章 相關報告

Global underactive bladder market is projected to register a CAGR of 5.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.

Market Segmentation:

Global Underactive Bladder Market, By Treatment (Pharmacotherapy, Surgical Methods, Urethral Assist Device, and Stem Cell and Gene Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Clinics, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of global underactive bladder market are:

Rising prevalence of bladder disorders

Increasing research and development to develop innovative treatments

Rising product launches

Market Players

The key market players operating in the global underactive bladder market are listed below:

Astellas Pharma Inc.

Aurobindo Pharma.

Boehringer Ingelheim International GmbH

Macleods Pharmaceuticals Ltd.

Orion Corporation

ONO PHARMACEUTICAL CO., LTD.

Novartis AG

Pfizer Inc.

Cipla Inc.

Dr. Reddy's Laboratories Ltd.

Teva Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

Almirall, S.A

Glenwood

Vesiflo, Inc.

Alkem Labs.

TABLE OF CONTENTS

1 INTRODUCTION 47

  • 1.1 OBJECTIVES OF THE STUDY 47
  • 1.2 MARKET DEFINITION 47
  • 1.3 OVERVIEW OF THE GLOBAL UNDERACTIVE BLADDER MARKET 47
  • 1.4 LIMITATIONS 49
  • 1.5 MARKETS COVERED 49

2 MARKET SEGMENTATION 52

  • 2.1 MARKETS COVERED 52
  • 2.2 GEOGRAPHICAL SCOPE 53
  • 2.3 YEARS CONSIDERED FOR THE STUDY 54
  • 2.4 CURRENCY AND PRICING 54
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 55
  • 2.6 MULTIVARIATE MODELLING 58
  • 2.7 PRODUCT SEGMENT LIFELINE CURVE 58
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 59
  • 2.9 DBMR MARKET POSITION GRID 60
  • 2.10 MARKET APPLICATION COVERAGE GRID 61
  • 2.11 VENDOR SHARE ANALYSIS 62
  • 2.12 SECONDARY SOURCES 63
  • 2.13 ASSUMPTIONS 63

3 EXECUTIVE SUMMARY 64

4 PREMIUM INSIGHTS 68

  • 4.1 PESTEL ANALYSIS 70
  • 4.2 PORTER'S FIVE FORCES 71
  • 4.3 EPIDEMIOLOGY 72
  • 4.4 THE IMPORTANCE OF UNDERSTANDING PATENTS- 74
    • 4.4.1 DOXAZOSIN 74
    • 4.4.2 BETHANECHOL CHLORIDE 81
    • 4.4.3 TAMSULOSIN HYDROCHLORIDE 89
  • 4.5 CLINICAL TRIALS FOR UNDERACTIVE BLADDER 91
    • 4.5.1 EU CLINICAL TRIALS REGISTER- 100
  • 4.6 MERGER & ACQUISITION IN HEALTHCARE INDUSTRY 103
  • 4.7 M&A DEALS IN 2021 BY TARGET COMPANY TERRITORY: 105
  • 4.8 CROSS-BORDER DEALS: 106
  • 4.9 OUTLOOK FOR 2022: 106
  • 4.10 PATIENT ENROLMENT STRATEGIES 107
  • 4.11 FACTORS AFFECTING PATIENT RECRUITMENT: 108
  • 4.12 CHALLENGES: 108
  • 4.13 PATIENT FUNNEL ANALYSIS: 108
  • 4.14 RECOMMENDATIONS 109
    • 4.14.1 USE OF TECHNOLOGY: 109
    • 4.14.2 PARTICIPANT CHARACTERISTICS: 109
    • 4.14.3 RECRUITER CHARACTERISTICS: 109
    • 4.14.4 SYSTEMS & PROCEDURES: 109
    • 4.14.5 LOCATION: 110
    • 4.14.6 NATURE OF RESEARCH: 110
  • 4.15 CONCLUSION: 110
  • 4.16 UNDERACTIVE BLADDER PATIENT FLOW DIAGRAM 111
  • 4.17 WHAT CAUSES UNDERACTIVE BLADDER? 111
    • 4.17.1 CAUSES OF UNDERACTIVE BLADDER INCLUDE 111
    • 4.17.2 TESTS TO EVALUATE UNDERACTIVE BLADDER 111
  • 4.18 UNDERACTIVE BLADDER INVESTIGATIONAL PRODUCTS- 112

5 GLOBAL UNDERACTIVE BLADDER MARKET: REGULATIONS 115

6 MARKET OVERVIEW 117

  • 6.1 DRIVERS 119
    • 6.1.1 INCREASING PREVALENCE OF NEUROGENIC DISORDER 119
    • 6.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF UNDERACTIVE BLADDER TREATMENT 119
    • 6.1.3 FAVOURABLE REIMBURSEMENT SCENARIO 120
    • 6.1.4 RISING HEALTHCARE EXPENDITURE 120
  • 6.2 RESTRAINTS 121
    • 6.2.1 HIGH COST OF RESEARCH AND DEVELOPMENT 121
    • 6.2.2 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL 121
  • 6.3 OPPORTUNITIES 122
    • 6.3.1 RISING UROLOGIC COMPLICATIONS OF DIABETES 122
    • 6.3.2 PRESENCE OF NOVEL PIPELINE DRUGS 123
    • 6.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM 123
  • 6.4 CHALLENGES 123
    • 6.4.1 LACK OF PROPER TREATMENT 123
    • 6.4.2 RISK INVOLVED DURING TREATMENT OF UNDERACTIVE BLADDER 124

7 GLOBAL UNDERACTIVE BLADDER MARKET, BY TYPE 125

  • 7.1 OVERVIEW 126
  • 7.2 PHARMACOTHERAPY 129
    • 7.2.1 ALPHA-BLOCKERS 130
    • 7.2.2 MUSCARINIC AGONISTS 130
    • 7.2.3 CHOLINESTERASE INHIBITOR 130
      • 7.2.3.1 BY DRUGS 130
        • 7.2.3.1.1 TAMSULOSIN 131
        • 7.2.3.1.2 DOXAZOSIN 131
        • 7.2.3.1.3 DISTIGMINE 131
        • 7.2.3.1.4 BETHANECHOL 131
        • 7.2.3.1.5 OTHERS 131
    • 7.2.4 BY PRODUCT TYPES 131
      • 7.2.4.1 GENERICS 132
      • 7.2.4.2 BRANDED 132
        • 7.2.4.2.1 FLOMAX 132
        • 7.2.4.2.2 ALFADIL 132
        • 7.2.4.2.3 GRAVITOR 132
        • 7.2.4.2.4 URIVOID 132
        • 7.2.4.2.5 OTHERS 132
  • 7.3 SURGICAL METHODS 133
    • 7.3.1 SURGICAL NERVE STIMULATION 134
    • 7.3.2 REDUCTION CYSTOPLASTY 134
    • 7.3.3 SURGERIES FOR BLADDER OBSTRUCTION 134
    • 7.3.4 INJECTION INTO EXTERNAL SPHINCTER 134
    • 7.3.5 OTHERS 134
  • 7.4 URETHRAL ASSIS DEVICE 135
    • 7.4.1 INFLOW INTRAURETHRAL VALVE PUMP 136
  • 7.5 STEM CELL AND GENE THERAPIES 137
    • 7.5.1 NERVE GROWTH FACTOR 139
    • 7.5.2 GLIAL-CELL DERIVE NEUTOPHIC FACTORGLIAL 139
    • 7.5.3 NEUTOPHIN-3 DERIVES FROM GLIALL CELLS 139

8 GLOBAL UNDERACTIVE BLADDER MARKET,BY ROUTE OF ADMINISTRATION 140

  • 8.1 OVERVIEW 141
  • 8.2 PARENTERAL 144
  • 8.3 ORAL 144
  • 8.4 OTHERS 146

9 GLOBAL UNDERACTIVE BLADDER MARKET , BY END USER 147

  • 9.1 OVERVIEW 148
  • 9.2 HOSPITALS 151
  • 9.3 CLINICS 151
  • 9.4 ACADEMIC AND RESEARCH 153
  • 9.5 OTHERS 153

10 GLOBAL UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL 155

  • 10.1 OVERVIEW 156
  • 10.2 HOSPITAL PHARMACY 159
  • 10.3 RETAIL PHARMACY 159
  • 10.4 OTHERS 161

11 GLOBAL UNDERACTIVE BLADDER MARKET, BY REGION 162

  • 11.1 OVERVIEW 163
  • 11.2 NORTH AMERICA 168
    • 11.2.1 U.S. 177
    • 11.2.2 CANADA 181
    • 11.2.3 MEXICO 186
  • 11.3 EUROPE 190
    • 11.3.1 GERMANY 199
    • 11.3.2 FRANCE 203
    • 11.3.3 U.K. 207
    • 11.3.4 ITALY 211
    • 11.3.5 RUSSIA 216
    • 11.3.6 SPAIN 220
    • 11.3.7 TURKEY 224
    • 11.3.8 NETHERLANDS 228
    • 11.3.9 SWITZERLAND 233
    • 11.3.10 POLAND 238
    • 11.3.11 AUSTRIA 242
    • 11.3.12 HUNGARY 246
    • 11.3.13 NORWAY 250
    • 11.3.14 IRELAND 254
    • 11.3.15 LITHUANIA 258
    • 11.3.16 REST OF EUROPE 263
  • 11.4 ASIA-PACIFIC 264
    • 11.4.1 CHINA 273
    • 11.4.2 JAPAN 277
    • 11.4.3 INDIA 281
    • 11.4.4 SOUTH KOREA 285
    • 11.4.5 AUSTRALIA 289
    • 11.4.6 SINGAPORE 293
    • 11.4.7 THAILAND 297
    • 11.4.8 INDONESIA 301
    • 11.4.9 PHILIPPINES 305
    • 11.4.10 MALAYSIA 309
    • 11.4.11 VIETNAM 313
    • 11.4.12 REST OF ASIA-PACIFIC 317
  • 11.5 SOUTH AMERICA 318
    • 11.5.1 BRAZIL 327
    • 11.5.2 ARGENTINA 331
    • 11.5.3 PERU 335
    • 11.5.4 REST OF SOUTH AMERICA 339
  • 11.6 MIDDLE EAST AND AFRICA 340
    • 11.6.1 SOUTH AFRICA 349
    • 11.6.2 SAUDI ARABIA 353
    • 11.6.3 U.A.E 357
    • 11.6.4 ISRAEL 361
    • 11.6.5 EGYPT 365
    • 11.6.6 KUWAIT 369
    • 11.6.7 REST OF MIDDLE EAST AND AFRICA 373

12 GLOBAL UNDERACTIVE BLADDER MARKET: COMPANY LANDSCAPE 374

  • 12.1 COMPANY SHARE ANALYSIS: GLOBAL 374
  • 12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 375
  • 12.3 COMPANY SHARE ANALYSIS: EUROPE 376
  • 12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 377

13 SWOT ANALYSIS 378

14 COMPANY PROFILES 379

  • 14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 379
    • 14.1.1 COMPANY SNAPSHOT 379
    • 14.1.2 COMPANY SHARE ANALYSIS 379
    • 14.1.3 PRODUCT PORTFOLIO 380
    • 14.1.4 RECENT DEVELOPMENT 380
  • 14.2 PFIZER INC. 381
    • 14.2.1 COMPANY SNAPSHOT 381
    • 14.2.2 REVENUE ANALYSIS 381
    • 14.2.3 COMPANY SHARE ANALYSIS 382
    • 14.2.4 PRODUCT PORTFOLIO 382
    • 14.2.5 RECENT DEVELOPMENT 382
  • 14.3 SUN PHARMACEUTICAL INDUSTRIES LTD. 383
    • 14.3.1 COMPANY SNAPSHOT 383
    • 14.3.2 REVENUE ANALYSIS 383
    • 14.3.3 COMPANY SHARE ANALYSIS 384
    • 14.3.4 PRODUCT PORTFOLIO 384
    • 14.3.5 RECENT DEVELOPMENT 384
  • 14.4 TEVA PHARMACEUTICAL INDUSTRIES LTD 385
    • 14.4.1 COMPANY SNAPSHOT 385
    • 14.4.2 REVENUE ANALYSIS 385
    • 14.4.3 COMPANY SHARE ANALYSIS 386
    • 14.4.4 PRODUCT PORTFOLIO 386
    • 14.4.5 RECENT DEVELOPMENT 386
  • 14.5 NOVARTIS AG 387
    • 14.5.1 COMPANY SNAPSHOT 387
    • 14.5.2 REVENUE ANALYSIS 387
    • 14.5.3 COMPANY SHARE ANALYSIS 388
    • 14.5.4 PRODUCT PORTFOLIO 388
    • 14.5.5 RECENT DEVELOPMENT 388
  • 14.6 DR. REDDY'S LABORATORIES LTD. 389
    • 14.6.1 COMPANY SNAPSHOT 389
    • 14.6.2 REVENUE ANALYSIS 389
    • 14.6.3 PRODUCT PORTFOLIO 390
    • 14.6.4 RECENT DEVELOPMENT 390
  • 14.7 ASTELLAS PHARMA INC. 391
    • 14.7.1 COMPANY SNAPSHOT 391
    • 14.7.2 REVENUE ANALYSIS 391
    • 14.7.3 PRODUCT PORTFOLIO 392
    • 14.7.4 RECENT DEVELOPMENT 392
  • 14.8 ORION CORPORATION. 393
    • 14.8.1 COMPANY SNAPSHOT 393
    • 14.8.2 REVENUE ANALYSIS 393
    • 14.8.3 PRODUCT PORTFOLIO 394
    • 14.8.4 RECENT DEVELOPMENT 394
  • 14.9 ALKEM LABS. 395
    • 14.9.1 COMPANY SNAPSHOT 395
    • 14.9.2 REVENUE ANALYSIS 395
    • 14.9.3 PRODUCT PORTFOLIO 396
    • 14.9.4 RECENT DEVELOPMENT 396
  • 14.10 ALMIRALL, S.A 397
    • 14.10.1 COMPANY SNAPSHOT 397
    • 14.10.2 REVENUE ANALYSIS 397
    • 14.10.3 PRODUCT PORTFOLIO 398
    • 14.10.4 RECENT DEVELOPMENT 398
  • 14.11 AUROBINDO PHARMA. 399
    • 14.11.1 COMPANY SNAPSHOT 399
    • 14.11.2 REVENUE ANALYSIS 399
    • 14.11.3 PRODUCT PORTFOLIO 400
    • 14.11.4 RECENT DEVELOPMENT 400
  • 14.12 CIPLA INC. 401
    • 14.12.1 COMPANY SNAPSHOT 401
    • 14.12.2 REVENUE ANALYSIS 401
    • 14.12.3 PRODUCT PORTFOLIO 402
    • 14.12.4 RECENT DEVELOPMENT 402
  • 14.13 GLENWOOD 403
    • 14.13.1 COMPANY SNAPSHOT 403
    • 14.13.2 PRODUCT PORTFOLIO 403
    • 14.13.3 RECENT DEVELOPMENT 403
  • 14.14 MACLEODS PHARMACEUTICALS LTD. 404
    • 14.14.1 COMPANY SNAPSHOT 404
    • 14.14.2 REVENUE ANALYSIS 404
    • 14.14.3 PRODUCT PORTFOLIO 405
    • 14.14.4 RECENT DEVELOPMENT 405
  • 14.15 ONO PHARMACEUTICAL CO., LTD. 406
    • 14.15.1 COMPANY SNAPSHOT 406
    • 14.15.2 REVENUE ANALYSIS 406
    • 14.15.3 PRODUCT PORTFOLIO 407
    • 14.15.4 RECENT DEVELOPMENT 407
  • 14.16 VESIFLO, INC. 408
    • 14.16.1 COMPANY SNAPSHOT 408
    • 14.16.2 PRODUCT PORTFOLIO 408
    • 14.16.3 RECENT DEVELOPMENTS 408

15 QUESTIONNAIRE 409

16 RELATED REPORTS 411

LIST OF TABLES

  • TABLE 1 TOTAL 40 DOXAZOSIN DRUGS WERE DISCONTINUED FROM THE MARKET 74
  • TABLE 2 TOTAL 38 DOXAZOSIN DRUGS ARE STILL IN THE MARKET 77
  • TABLE 3 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (DOXAZOSIN) BY COMPANY 80
  • TABLE 4 TOTAL 58 DRUGS DISCONTINUED 81
  • TABLE 5 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (BETHANECHOL CHLORIDE) BY COMPANY 88
  • TABLE 6 OUT OF 3,128 STUDIES ON BLADDER DISORDER, ONLY 22 STUDIES ARE ONGOING FOR THE UAB- 91
  • TABLE 7 THESE CLINICAL TRIALS ARE MOSTLY RECRUITING/ONGOING IN DIFFERENT REGIONS OF THE WORLD- 91
  • TABLE 8 TOP ACQUISITIONS OF 2021 RANKED BY TOTAL DEAL VALUE: 104
  • TABLE 9 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED 116
  • TABLE 10 GLOBAL UNDERACTIVE BLADDER MARKET, TYPE, 2020-2029 (USD MILLION) 128
  • TABLE 11 GLOBAL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 129
  • TABLE 12 GLOBAL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 130
  • TABLE 13 GLOBAL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 130
  • TABLE 14 GLOBAL BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 130
  • TABLE 15 GLOBAL BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 131
  • TABLE 16 GLOBAL BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 132
  • TABLE 17 GLOBAL SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 133
  • TABLE 18 GLOBAL SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 134
  • TABLE 19 GLOBAL URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 135
  • TABLE 20 GLOBAL URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 136
  • TABLE 21 GLOBAL STEM CELL AND GENE THERAPIES IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 137
  • TABLE 22 GLOBAL STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 137
  • TABLE 23 GLOBAL UNDERACTIVE BLADDER MARKET , BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 143
  • TABLE 24 GLOBAL PARENTERAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 144
  • TABLE 25 GLOBAL ORAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 145
  • TABLE 26 GLOBAL OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 146
  • TABLE 27 GLOBAL UNDERACTIVE BLADDER MARKET , BY END USER, 2020-2029 (USD MILLION) 150
  • TABLE 28 GLOBAL HOSPITALS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 151
  • TABLE 29 GLOBAL CLINICS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 152
  • TABLE 30 GLOBAL ACADEMIC AND RESEARCH IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 153
  • TABLE 31 GLOBAL OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 154
  • TABLE 32 GLOBAL UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION) 158
  • TABLE 33 GLOBAL HOSPITAL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 159
  • TABLE 34 GLOBAL RETAIL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 160
  • TABLE 35 GLOBAL OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 161
  • TABLE 36 GLOBAL UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION) 167
  • TABLE 37 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 172
  • TABLE 38 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 172
  • TABLE 39 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 172
  • TABLE 40 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 172
  • TABLE 41 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 173
  • TABLE 42 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 173
  • TABLE 43 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP) 173
  • TABLE 44 NORTH AMERICA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 174
  • TABLE 45 NORTH AMERICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 174
  • TABLE 46 NORTH AMERICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 174
  • TABLE 47 NORTH AMERICA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP) 174
  • TABLE 48 NORTH AMERICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 175
  • TABLE 49 NORTH AMERICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 175
  • TABLE 50 NORTH AMERICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 175
  • TABLE 51 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION) 175
  • TABLE 52 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION) 176
  • TABLE 53 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION) 176
  • TABLE 54 U.S. UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 177
  • TABLE 55 U.S. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 177
  • TABLE 56 U.S. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 177
  • TABLE 57 U.S. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 177
  • TABLE 58 U.S. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 178
  • TABLE 59 U.S. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP) 178
  • TABLE 60 U.S. BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 178
  • TABLE 61 U.S. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 178
  • TABLE 62 U.S. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 179
  • TABLE 63 U.S. BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP) 179
  • TABLE 64 U.S. SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 179
  • TABLE 65 U.S. URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 179
  • TABLE 66 U.S. STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 180
  • TABLE 67 U.S. UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION) 180
  • TABLE 68 U.S. UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION) 180
  • TABLE 69 U.S. UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION) 180
  • TABLE 70 CANADA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 181
  • TABLE 71 CANADA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 181
  • TABLE 72 CANADA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 181
  • TABLE 73 CANADA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 181
  • TABLE 74 CANADA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 182
  • TABLE 75 CANADA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP) 182
  • TABLE 76 CANADA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 182
  • TABLE 77 CANADA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 182
  • TABLE 78 CANADA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 183
  • TABLE 79 CANADA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP) 183
  • TABLE 80 CANADA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 183
  • TABLE 81 CANADA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 184
  • TABLE 82 CANADA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 184
  • TABLE 83 CANADA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION) 184
  • TABLE 84 CANADA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION) 184
  • TABLE 85 CANADA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION) 185
  • TABLE 86 MEXICO UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 186
  • TABLE 87 MEXICO PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 186
  • TABLE 88 MEXICO PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 186
  • TABLE 89 MEXICO BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 186
  • TABLE 90 MEXICO BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 187
  • TABLE 91 MEXICO BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP) 187
  • TABLE 92 MEXICO BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 187
  • TABLE 93 MEXICO BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 187
  • TABLE 94 MEXICO BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 188
  • TABLE 95 MEXICO BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP) 188
  • TABLE 96 MEXICO SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 188
  • TABLE 97 MEXICO URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 188
  • TABLE 98 MEXICO STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 189
  • TABLE 99 MEXICO UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION) 189
  • TABLE 100 MEXICO UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION) 189
  • TABLE 101 MEXICO UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION) 189
  • TABLE 102 EUROPE UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 194
  • TABLE 103 EUROPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 194
  • TABLE 104 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 194
  • TABLE 105 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 195
  • TABLE 106 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 195
  • TABLE 107 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 195
  • TABLE 108 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP) 195
  • TABLE 109 EUROPE BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 196
  • TABLE 110 EUROPE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 196
  • TABLE 111 EUROPE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 196
  • TABLE 112 EUROPE BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP) 196
  • TABLE 113 EUROPE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 197
  • TABLE 114 EUROPE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 197
  • TABLE 115 EUROPE STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 197
  • TABLE 116 EUROPE UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION) 197
  • TABLE 117 EUROPE UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION) 198
  • TABLE 118 EUROPE UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION) 198
  • TABLE 119 GERMANY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 199
  • TABLE 120 GERMANY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 199
  • TABLE 121 GERMANY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 199
  • TABLE 122 GERMANY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 199
  • TABLE 123 GERMANY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 200
  • TABLE 124 GERMANY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP) 200
  • TABLE 125 GERMANY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 200
  • TABLE 126 GERMANY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 200
  • TABLE 127 GERMANY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 201
  • TABLE 128 GERMANY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP) 201
  • TABLE 129 GERMANY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 201
  • TABLE 130 GERMANY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 201
  • TABLE 131 GERMANY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 202
  • TABLE 132 GERMANY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION) 202
  • TABLE 133 GERMANY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION) 202
  • TABLE 134 GERMANY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION) 202
  • TABLE 135 FRANCE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 203
  • TABLE 136 FRANCE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 203
  • TABLE 137 FRANCE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 203
  • TABLE 138 FRANCE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 203
  • TABLE 139 FRANCE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 204
  • TABLE 140 FRANCE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP) 204
  • TABLE 141 FRANCE BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 204
  • TABLE 142 FRANCE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 204
  • TABLE 143 FRANCE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 205
  • TABLE 144 FRANCE BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP) 205
  • TABLE 145 FRANCE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 205
  • TABLE 146 FRANCE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 205
  • TABLE 147 FRANCE STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 206
  • TABLE 148 FRANCE UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION) 206
  • TABLE 149 FRANCE UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION) 206
  • TABLE 150 FRANCE UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION) 206
  • TABLE 151 U.K. UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 207
  • TABLE 152 U.K. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 207
  • TABLE 153 U.K. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 207
  • TABLE 154 U.K. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 207
  • TABLE 155 U.K. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 208
  • TABLE 156 U.K. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP) 208
  • TABLE 157 U.K. BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 208
  • TABLE 158 U.K. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 208
  • TABLE 159 U.K. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 209
  • TABLE 160 U.K. BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP) 209
  • TABLE 161 U.K. SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 209
  • TABLE 162 U.K. URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 209
  • TABLE 163 U.K. STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 210
  • TABLE 164 U.K. UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION) 210
  • TABLE 165 U.K. UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION) 210
  • TABLE 166 U.K. UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION) 210
  • TABLE 167 ITALY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 211
  • TABLE 168 ITALY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 211
  • TABLE 169 ITALY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 211
  • TABLE 170 ITALY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 211
  • TABLE 171 ITALY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 212
  • TABLE 172 ITALY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP) 212
  • TABLE 173 ITALY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 212
  • TABLE 174 ITALY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 212
  • TABLE 175 ITALY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 213
  • TABLE 176 ITALY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP) 213
  • TABLE 177 ITALY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 213
  • TABLE 178 ITALY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 214
  • TABLE 179 ITALY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 214
  • TABLE 180 ITALY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION) 214
  • TABLE 181 ITALY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION) 214
  • TABLE 182 ITALY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION) 215
  • TABLE 183 RUSSIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 216
  • TABLE 184 RUSSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 216
  • TABLE 185 RUSSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 216
  • TABLE 186 RUSSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 216
  • TABLE 187 RUSSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 217
  • TABLE 188 RUSSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP) 217
  • TABLE 189 RUSSIA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 217
  • TABLE 190 RUSSIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 217
  • TABLE 191 RUSSIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 218
  • TABLE 192 RUSSIA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP) 218
  • TABLE 193 RUSSIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 218
  • TABLE 194 RUSSIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 218
  • TABLE 195 RUSSIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 219
  • TABLE 196 RUSSIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION) 219
  • TABLE 197 RUSSIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION) 219
  • TABLE 198 RUSSIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION) 219
  • TABLE 199 SPAIN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 220
  • TABLE 200 SPAIN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 220
  • TABLE 201 SPAIN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 220
  • TABLE 202 SPAIN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 220
  • TABLE 203 SPAIN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 221
  • TABLE 204 SPAIN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP) 221
  • TABLE 205 SPAIN BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 221
  • TABLE 206 SPAIN BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 221
  • TABLE 207 SPAIN BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 222
  • TABLE 208 SPAIN BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP) 222
  • TABLE 209 SPAIN SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 222
  • TABLE 210 SPAIN URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 222
  • TABLE 211 SPAIN STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 223
  • TABLE 212 SPAIN UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION) 223
  • TABLE 213 SPAIN UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION) 223
  • TABLE 214 SPAIN UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION) 223
  • TABLE 215 TURKEY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 224
  • TABLE 216 TURKEY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 224
  • TABLE 217 TURKEY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 224
  • TABLE 218 TURKEY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 224
  • TABLE 219 TURKEY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 225
  • TABLE 220 TURKEY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP) 225
  • TABLE 221 TURKEY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 225
  • TABLE 222 TURKEY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 225
  • TABLE 223 TURKEY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 226
  • TABLE 224 TURKEY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP) 226
  • TABLE 225 TURKEY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 226
  • TABLE 226 TURKEY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 226
  • TABLE 227 TURKEY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 227
  • TABLE 228 TURKEY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION) 227
  • TABLE 229 TURKEY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION) 227
  • TABLE 230 TURKEY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION) 227
  • TABLE 231 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 228
  • TABLE 232 NETHERLANDS PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 228
  • TABLE 233 NETHERLANDS PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 228
  • TABLE 234 NETHERLANDS BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 228
  • TABLE 235 NETHERLANDS BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 229
  • TABLE 236 NETHERLANDS BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP) 229
  • TABLE 237 NETHERLANDS BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 229
  • TABLE 238 NETHERLANDS BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 229
  • TABLE 239 NETHERLANDS BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS) 230
  • TABLE 240 NETHERLANDS BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP) 230
  • TABLE 241 NETHERLANDS SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 230
  • TABLE 242 NETHERLANDS URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 231
  • TABLE 243 NETHERLANDS STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 231
  • TABLE 244 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION) 231
  • TABLE 245 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION) 231
  • TABLE 246 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION) 232
  • TABLE 247 SWITZERLAND UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION) 233
  • TABLE 248 SWITZERLAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION) 233